Industry Pioneer, David Watson, Joins United Cannabis Corp Advisory Board
August 24 2017 - 8:33AM
Access Wire
Watson Will Focus On Breeding Narrow;
Leaf Indica And High Terpene Cannabis
Varieties
DENVER, CO / ACCESSWIRE / August 24, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced the appointment of David Watson to the
Company's Advisory Board.
Mr. Watson, founder and Chief Executive Officer of HortaPharm
B.V., the world's first established medical cannabis corporation,
is renowned in the industry. Credited by many for assembling the
world's most comprehensive cannabis-seed library, he is also
responsible for securing protection for 29 cultivars under the
International Union for the Protection of New Varieties of Plants
(UPOV) breeder's rights.
Selfing, the proprietary breeding technique developed under his
guidance, resulted in HortaPharm becoming the world's first breeder
to develop homozygote cannabis, in which both sets of chromosomes
are identical. This facilitates the mass production of plants with
a consistent cannabinoid profile; a critical factor in
pharmaceutical development. To that end, in 1998, HortaPharm began
working with GW Pharmaceuticals, assisting it in selecting and
supplying the cultivars used to produce Sativex®, and other GW
products.
Mr. Watson is also co-founder of the International Hemp
Association, a non-profit educational group dedicated to the
advancement of cannabis through the dissemination of information,
and an activist working in the United States and internationally to
change laws regarding the cultivation of industrial hemp. Mr.
Watson co-authored Hemp Diseases and Pests (2000) and
contributed to Cannabis and Cannabinoids, Marijuana and
Cannabinoids. He has also written a number of peer-reviewed
articles.
The Company's Advisory Board is tasked with helping the Company
advance and protect the development of its proprietary
formulations, including managing the clinical trial process, patent
protection, new product research, and development, as well as
identifying and pursuing potential strategic relationships and
markets. Mr. Watson's focus will be the development of NLD
equatorial and tropical recreational varieties and industrial
varieties as well as high terpene varieties.
Commenting on the appointment, Mr. Watson stated, "I look
forward to working with United Cannabis to develop cannabis
varieties with unique cannabinoid and terpene profiles."
Earnest Blackmon, Chief Executive Officer of United Cannabis,
added, "We are thrilled to announce that David has joined our
Advisory Board. He is legendary within the industry, and his
knowledge regarding the identification and cultivation of specific
cannabis varieties will be indispensable as we continue our efforts
to create effective cannabis-centric compounds to assist patients
suffering from a broad spectrum of conditions. I cannot wait to
begin working closely with him."
About United Cannabis Corporation
The Company's Prana Bio Medicinal products provide patients a
way to mix/match cannabinoids for therapeutic purpose. These
products, licensed to regulated marijuana dispensaries, are broken
into 5 categories that are available in capsules, sublingual's, and
topical delivery methods. The Company uses a patent-pending
infusion process utilizing select fatty acids, lipids, and specific
combination of cannabis derived terpenes to increase
bioavailability.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors, created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation